What is HGH Frag 176-191

HGH Frag 176-191 is a synthetic peptide fragment of human Growth Hormone studied in research exclusively for its targeted lipolytic (fat-burning) properties. It is intended exclusively for research use.

Regarding its chemical identity, HGH has a molecular formula of C78H125N23O23S2 and a molecular weight of 1817.1 g/mol. Its reported canonical sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include HGH.

Product for research use.

Mechanism of action of HGH

HGH Frag 176-191 mimics the lipolytic actions of the full-length Growth Hormone molecule without binding to the HGH receptor. It stimulates beta-3 adrenergic receptors, leading to the breakdown of fat (lipolysis) and inhibiting the formation of new fat (lipogenesis) in adipocytes.

Pharmacokinetics and pharmacodynamics of HGH

The peptide has a very short half-life and acts rapidly on adipose tissue. Because it is only a small fragment (amino acids 176-191) of the full 191-amino acid HGH chain, it does not stimulate IGF-1 production or affect carbohydrate metabolism.

Scientific evidence on HGH

The available evidence on HGH is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated primarily in models of obesity and metabolic syndrome. Preclinical data shows it significantly reduces body fat, particularly visceral fat, without inducing insulin resistance or hyperglycemia, which are common side effects of full-length HGH.

HGH applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

HGH protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for HGH, so no trial schemes or quantities are specified.

The presentations of this product (Various (e.g., 2MG, 5MG)) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of HGH

As a general guideline for laboratory handling, lyophilized peptides such as HGH are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the Various (e.g., 2MG, 5MG) contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

HGH Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented HGH security profile

The documented safety information in open sources for HGH is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Due to its targeted action, it has a highly favorable theoretical safety profile compared to HGH. It does not cause water retention, cell proliferation, or altered glucose tolerance. Long-term safety in humans remains unverified.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

HGH in a comparative context

Unlike full-length HGH, which has broad systemic effects (growth, muscle building, insulin resistance), HGH Frag 176-191 is isolated specifically for fat loss. It is a metabolic tool rather than an anabolic one.

History and development of HGH

Developed by researchers at Monash University in Australia who isolated the specific region of the HGH molecule responsible for fat metabolism, successfully decoupling the fat-burning effects from the anabolic and diabetogenic effects of HGH.